Cautionary Note Regarding Forward-Looking Statements:The statements in this press release that relate to future plans, events orperformance, are forward-looking statements that involve risks anduncertainties, including risks associated with uncertainties pertaining tocustomer orders, demand for services and products, development of markets forthe company`s services and products and other risks identified in the company`sSEC filings, and in particular its Annual Report on Form 10-K. Actual results,events and performance may differ materially, including the continuing demandfor personal protection equipment and the testing of same. Readers are cautionednot to place undue reliance on these forward-looking statements, which speakonly as of the date hereof. The company undertakes no obligation to releasepublicly the result of any revisions to these forward-looking statements thatmay be made to reflect events or circumstances after the date hereof or toreflect the occurrence of unanticipated events NATIONAL TECHNICAL SYSTEMS, INC. .

Treximet® Q1 2009 Total Prescriptions 14% Higher Than Q4 2008*CHAPEL HILL, N.C.–(Business Wire)–POZEN Inc. (NASDAQ:POZN),today announced results for the first quarter endedMarch 31, 2009. First Quarter ResultsPOZEN reported a net loss of ($3.5) million, or ($0.12) per share on a dilutedbasis, for the first quarter of 2009, compared to a net loss of ($7.4) million,or ($0.25) per share on a diluted basis, for the first quarter of 2008. For the first quarter of 2009, POZEN reported revenue of $8.8 million resultingfrom the amortization of upfront payments received pursuant to the collaborationagreement with AstraZeneca of $3.1 million, Treximet® royalties of $1.0 million,and revenue from development work performed under the AstraZeneca agreement of$4.7 million. Revenue for the first quarter ended March 31, 2008 totaled $7.8million. Operating expenses for the first quarter of 2009 totaled $12.5 million ascompared to $16.0 million for the comparable period in 2008. The decrease inoperating expenses was primarily due to a decrease in costs associated with thePN 400 program.

At March 31, 2009, cash, cash equivalents and short-term investments totaled$52.3 million compared to $61.7 million at December 31, 2008. The Company has anaccounts receivable balance of $5.9 million from AstraZeneca and GlaxoSmithKlineat March 31, 2009. Corporate HighlightsTreximetTreximet net sales totaled $20.3 million for GlaxoSmithKline in the firstquarter of 2009, generating royalty revenue of $1.0 million for POZEN. Accordingto IMS Health, total prescriptions of Treximet in the first quarter of 2009 were14% higher than the fourth quarter of 2008. Total prescriptions in March 2009were 30% higher than January 2009 and 27% higher than February 2009, reflectingsuccess of the promotional efforts by GlaxoSmithKline.*PN 400 ProgramUpon evaluation of the PN 400 clinical program, AstraZeneca will make a finaldetermination regarding the New Drug Application (NDA) filing with the UnitedStates Food and Drug Administration (FDA) The NDA submission is planned formid-2009. Pursuant to the collaboration agreement, POZEN expects to receive a$10 million milestone payment from AstraZeneca upon acceptance of the NDA by theFDA. PA ProgramIn February 2009, POZEN received written confirmation from the FDA thatendoscopic gastric ulcer incidence was an acceptable endpoint for the Phase 3clinical studies the Company proposed in its Special Protocol Assessmentsubmission for PA32540.

The Company is planning to begin Phase 3 studies in latesummer of 2009. POZEN does not plan to seek a license partner for PA32540 untilafter the commercialization strategy for the PA products is finalized. * Note: This information is an estimate derived from the use of informationunder license from the following IMS Health information service: NPA Plus forthe period October 2008 – March 2009. IMS expressly reserves all rights,including rights of copying, distribution and republication. First Quarter Results WebcastPOZEN will hold a webcast to present first quarter 2009 results and management`soutlook on Thursday, April 30, 2009 at 11:00 a.m Eastern time.

The webcast canbe accessed live and will be available for replay at About POZENPOZEN is a pharmaceutical company committed to developing therapeuticadvancements for diseases with unmet medical needs where it can improveefficacy, safety, and/or patient convenience. POZEN`s efforts are focusedprimarily on the development of pharmaceutical products for the treatment ofacute and chronic pain and other pain-related conditions. POZEN has developmentand commercialization alliances with GlaxoSmithKline for Treximet, which wasapproved in 2008 by the United States Food and Drug Administration for the acutetreatment of migraine attacks, with or without aura, in adults, and withAstraZeneca for proprietary fixed dose combinations of naproxen with the protonpump inhibitor esomeprazole magnesium in a single tablet for conditions such asosteoarthritis and rheumatoid arthritis in patients who are at risk fordeveloping NSAID-associated gastric ulcers. The Company`s common stock is tradedon The NASDAQ Stock Market under the symbol “POZN”. For detailed companyinformation, including copies of this and other press releases, see POZEN`swebsite: Statements included in this press release that are not historical in nature are”forward-looking statements” within the meaning of the “safe harbor” provisionsof the Private Securities Litigation Reform Act of 1995.